The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more ...

Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...